A Solution For Elan: It Strikes A Deal With J&J On Key Alzheimer's Assets

J&J gets to build its fledgling Alzheimer's program, while Elan gets cash to strengthen its balance sheet, plus a new minority shareholder and strong global partner.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet